http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112666359-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate | 2020-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112666359-B |
| titleOfInvention | Plasma ceramide as biomarker for predicting hepatic insufficiency after hepatectomy and application thereof |
| abstract | The invention belongs to the technical field of biological medicines, and relates to a biomarker for prognosis prediction of post-hepatectomy hepatic insufficiency, and discloses plasma ceramide as a biomarker for predicting post-hepatectomy hepatic insufficiency and application thereof, wherein an HPLC-MS/MS method is adopted to detect the concentration of the ceramide in human plasma, and clinical tests prove that the concentration of the ceramide is 18: 1-carbon ceramide (C18: 1-Cer) and/or 20: the level of 1-carbon ceramide (C20: 1-Cer) in pre-operative plasma samples from a liver dysfunction group after hepatectomy was significantly higher than that in a liver dysfunction group without hepatectomy. The invention is used for the auxiliary diagnosis and prognosis judgment of the hepatic insufficiency after the hepatectomy, and has guiding significance for the clinical treatment in the perioperative period. |
| priorityDate | 2020-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.